NovaVision, a wholly owned subsidiary of Vycor Medical, announced that it had showcased the European version of its Internet-delivered NovaVision Therapy Suite at the 30th Annual GNP Conference in Lübeck, Germany last week.
NovaVision’s therapy suite consists of Vision Restoration Therapy (VRT) and NeuroEyeCoach, an eye-movement compensation therapy.
The therapy suite, which is delivered directly to patients’ computers via the Internet, is designed to provide broad benefits to those who suffer from vision disorders due to stroke or brain injury. NovaVision plans to launch the therapy suite across Europe in the fourth quarter of 2015, initially in German and English.
The GNP, or Society for Neuropsychology, is the leading society for German-speaking neuropsychologists in Germany, Austria and Switzerland, with over 1,500 members, dedicated to the development and improvement of diagnostic and therapeutic techniques including patients with neurological brain damage.
GNP members play an influential and important role in the rehabilitation and referral of potential NovaVision patients in rehabilitation centers, clinics and physician practices, as well as playing an important role in clinical research.
GNP conference attendees who tried the German language version of the therapy suite were impressed by the ease of use, affordability for patients and the two therapies’ complementary, broad benefits.
Adrian Liddell, chairman of Vycor and managing director of NovaVision in Germany, commented: "We are encouraged by the positive reception of our NovaVision therapy suite launched in June in the U.S. We believe the anticipated launch of our Internet-delivered versions in Europe will enable us to offer a comprehensive and affordable therapy solution to patients and physicians out of our offices in Magdeburg, Germany and Aberdeen, UK.
Vycor Medical’s ViewSite Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam.